290 related articles for article (PubMed ID: 30683312)
1. Liraglutide protects against inflammatory stress in non-alcoholic fatty liver by modulating Kupffer cells M2 polarization via cAMP-PKA-STAT3 signaling pathway.
Li Z; Feng PP; Zhao ZB; Zhu W; Gong JP; Du HM
Biochem Biophys Res Commun; 2019 Feb; 510(1):20-26. PubMed ID: 30683312
[TBL] [Abstract][Full Text] [Related]
2. Liraglutide protects non-alcoholic fatty liver disease via inhibiting NLRP3 inflammasome activation in a mouse model induced by high-fat diet.
Zhu W; Feng PP; He K; Li SW; Gong JP
Biochem Biophys Res Commun; 2018 Oct; 505(2):523-529. PubMed ID: 30269815
[TBL] [Abstract][Full Text] [Related]
3. Liraglutide Improves Non-Alcoholic Fatty Liver Disease In Diabetic Mice By Modulating Inflammatory Signaling Pathways.
Luo Y; Yang P; Li Z; Luo Y; Shen J; Li R; Zheng H; Liang Y; Xia N
Drug Des Devel Ther; 2019; 13():4065-4074. PubMed ID: 31819375
[TBL] [Abstract][Full Text] [Related]
4. Effect of modulation of PPAR-γ activity on Kupffer cells M1/M2 polarization in the development of non-alcoholic fatty liver disease.
Luo W; Xu Q; Wang Q; Wu H; Hua J
Sci Rep; 2017 Mar; 7():44612. PubMed ID: 28300213
[TBL] [Abstract][Full Text] [Related]
5. The Glucagon-Like Peptide-1 Analogue Liraglutide Inhibits Oxidative Stress and Inflammatory Response in the Liver of Rats with Diet-Induced Non-alcoholic Fatty Liver Disease.
Gao H; Zeng Z; Zhang H; Zhou X; Guan L; Deng W; Xu L
Biol Pharm Bull; 2015; 38(5):694-702. PubMed ID: 25947915
[TBL] [Abstract][Full Text] [Related]
6. Liraglutide attenuates type 2 diabetes mellitus-associated non-alcoholic fatty liver disease by activating AMPK/ACC signaling and inhibiting ferroptosis.
Guo T; Yan W; Cui X; Liu N; Wei X; Sun Y; Fan K; Liu J; Zhu Y; Wang Z; Zhang Y; Chen L
Mol Med; 2023 Sep; 29(1):132. PubMed ID: 37770820
[TBL] [Abstract][Full Text] [Related]
7. Biochemical and histological characterisation of an experimental rodent model of non-alcoholic steatohepatitis - Effects of a peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist and a glucagon-like peptide-1 analogue.
Daniels SJ; Leeming DJ; Detlefsen S; Bruun MF; Hjuler ST; Henriksen K; Hein P; Karsdal MA; Brockbank S; Cruwys S
Biomed Pharmacother; 2019 Mar; 111():926-933. PubMed ID: 30841472
[TBL] [Abstract][Full Text] [Related]
8. Fisetin Protects Against Hepatic Steatosis Through Regulation of the Sirt1/AMPK and Fatty Acid β-Oxidation Signaling Pathway in High-Fat Diet-Induced Obese Mice.
Liou CJ; Wei CH; Chen YL; Cheng CY; Wang CL; Huang WC
Cell Physiol Biochem; 2018; 49(5):1870-1884. PubMed ID: 30235452
[TBL] [Abstract][Full Text] [Related]
9. [Liraglutide protects against nonalcoholic fatty liver disease in ApoE knockout mice with high-fat diet and silenced Acrp30 by increasing AMPK].
Zhao XY; Zhang LL; Suolang QZ; Yang GY; Li L; Li SB; Chen WW
Zhonghua Gan Zang Bing Za Zhi; 2014 Nov; 22(11):849-53. PubMed ID: 25531383
[TBL] [Abstract][Full Text] [Related]
10. GLP-1 analogue improves hepatic lipid accumulation by inducing autophagy via AMPK/mTOR pathway.
He Q; Sha S; Sun L; Zhang J; Dong M
Biochem Biophys Res Commun; 2016 Aug; 476(4):196-203. PubMed ID: 27208776
[TBL] [Abstract][Full Text] [Related]
11. Oridonin regulates the polarized state of Kupffer cells to alleviate nonalcoholic fatty liver disease through ROS-NF-κB.
Zhu Y; Ruan S; Shen H; Guan Q; Zhai L; Yang Y
Int Immunopharmacol; 2021 Dec; 101(Pt B):108290. PubMed ID: 34717194
[TBL] [Abstract][Full Text] [Related]
12. Liraglutide in combination with human umbilical cord mesenchymal stem cell could improve liver lesions by modulating TLR4/NF-kB inflammatory pathway and oxidative stress in T2DM/NAFLD rats.
Xu X; Wang W; Lin L; Chen P
Tissue Cell; 2020 Oct; 66():101382. PubMed ID: 32933722
[TBL] [Abstract][Full Text] [Related]
13. Regulation of lipid-induced macrophage polarization through modulating peroxisome proliferator-activated receptor-gamma activity affects hepatic lipid metabolism via a Toll-like receptor 4/NF-κB signaling pathway.
Wu HM; Ni XX; Xu QY; Wang Q; Li XY; Hua J
J Gastroenterol Hepatol; 2020 Nov; 35(11):1998-2008. PubMed ID: 32128893
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of liraglutide in treating type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease.
Tian F; Zheng Z; Zhang D; He S; Shen J
Biosci Rep; 2018 Dec; 38(6):. PubMed ID: 30473540
[TBL] [Abstract][Full Text] [Related]
15. The GLP-1R agonist liraglutide limits hepatic lipotoxicity and inflammatory response in mice fed a methionine-choline deficient diet.
Somm E; Montandon SA; Loizides-Mangold U; Gaïa N; Lazarevic V; De Vito C; Perroud E; Bochaton-Piallat ML; Dibner C; Schrenzel J; Jornayvaz FR
Transl Res; 2021 Jan; 227():75-88. PubMed ID: 32711187
[TBL] [Abstract][Full Text] [Related]
16. Liraglutide ameliorates obesity-related nonalcoholic fatty liver disease by regulating Sestrin2-mediated Nrf2/HO-1 pathway.
Han X; Ding C; Zhang G; Pan R; Liu Y; Huang N; Hou N; Han F; Xu W; Sun X
Biochem Biophys Res Commun; 2020 May; 525(4):895-901. PubMed ID: 32171530
[TBL] [Abstract][Full Text] [Related]
17. [Effects of liraglutide combined with vitamin D on non-alcoholic fatty liver induced by high fat in mice and its mechanism].
Wang F; Zhang HF
Zhongguo Ying Yong Sheng Li Xue Za Zhi; 2020 May; 36(3):261-264. PubMed ID: 32981283
[No Abstract] [Full Text] [Related]
18. Elafibranor and liraglutide improve differentially liver health and metabolism in a mouse model of non-alcoholic steatohepatitis.
Perakakis N; Stefanakis K; Feigh M; Veidal SS; Mantzoros CS
Liver Int; 2021 Aug; 41(8):1853-1866. PubMed ID: 33788377
[TBL] [Abstract][Full Text] [Related]
19. Galectin-12 modulates Kupffer cell polarization to alter the progression of nonalcoholic fatty liver disease.
Lee JL; Wang YC; Hsu YA; Chen CS; Weng RC; Lu YP; Chuang CY; Wan L
Glycobiology; 2023 Oct; 33(8):673-682. PubMed ID: 37504513
[TBL] [Abstract][Full Text] [Related]
20. Protective effect and mechanism of Qiwei Tiexie capsule on 3T3-L1 adipocytes cells and rats with nonalcoholic fatty liver disease by regulating LXRα, PPARγ, and NF-κB-iNOS-NO signaling pathways.
Suolang PC; Liu BQ; Chen J; De J; Nima ZB; Dunzhu CR
J Ethnopharmacol; 2019 May; 236():316-325. PubMed ID: 30851372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
